First generic Abilify approved

April 30, 2015

FDA approves first generic abilify
The first generic versions of the atypical antipsychotic drug Abilify (aripiprazole) have been approved by the U.S. Food and Drug Administration to treat schizophrenia or bipolar disorder.
(HealthDay)—The first generic versions of the atypical antipsychotic drug Abilify (aripiprazole) have been approved by the U.S. Food and Drug Administration to treat schizophrenia or bipolar disorder.

License to produce the drug in multiple strengths was approved for Alembic Pharmaceuticals, Hetero Labs, Teva Pharmaceuticals, and Torrent Pharmaceuticals, the agency said in a news release.

Bipolar disorder, also known as manic depression or manic-depressive illness, is a brain disorder that causes unusual moods and activities, affecting the ability to carry out day-to-day tasks. Symptoms typically include alternating periods of depression (lows) and increased activity and restlessness (highs).

Schizophrenia, another brain disorder, affects about 1 percent of Americans. Symptoms typically begin in people younger than 30, and include hearing voices, believing other people are controlling their minds or actions, and being suspicious and withdrawn.

As with other , generic Abilify's label will contain the FDA's most stringent boxed warning that the medication poses an increased risk of death among older people with dementia-related psychosis. The label also warns of an increased risk of suicidal thinking and behavior among children, teens and young adults.

The most common side effects of the drug are nausea, vomiting, constipation, headache, dizziness, body twitching, anxiety, insomnia and restlessness.

The FDA release included a statement that approved generic drugs are produced to the same quality standards as their brand-name counterparts.

Explore further: FDA: generic copaxone approved for multiple sclerosis

More information: Visit the FDA to learn more about this approval.

Related Stories

FDA: generic copaxone approved for multiple sclerosis

April 17, 2015
(HealthDay)—The first U.S. generic version of Copaxone (glatiramer acetate injection) has been approved by the Food and Drug Administration to treat multiple sclerosis.

First generic lexapro approved

March 14, 2012
(HealthDay) -- The Israeli drug maker Teva Pharmaceuticals has gained the first U.S. approval to market generic Lexapro (escitalopram) to treat depression and general anxiety disorder, the U.S. Food and Drug Administration ...

Generic form of nexium approved

January 26, 2015
(HealthDay)—The first generic version of the heartburn drug Nexium (esomeprazole) has been approved by the U.S. Food and Drug Administration.

Generic aciphex approved to treat chronic heartburn

November 8, 2013
(HealthDay)—The first generic versions of the anti-GERD drug Aciphex (rabeprazole sodium) have been approved by the U.S. Food and Drug Administration for people aged 12 and older, the agency said Friday.

Brintellix approved for major depressive disorder

October 1, 2013
(HealthDay)—Brintellix (vortioxetine) has been approved by the U.S. Food and Drug Administration to treat adults with major depressive disorder, often referred to as depression.

First generic versions of singulair approved

August 4, 2012
(HealthDay) -- The first generic versions of Singulair (montelukast sodium) have been approved by the U.S. Food and Drug Administration.

Recommended for you

Shortcut strategy for screening compounds with clinical potentials for drug development

December 4, 2018
Developing a new drug often takes years and costs hundreds of millions of dollars. A shortcut has now been reported in a study led by City University of Hong Kong (CityU), which can potentially reduce the time and costs of ...

Drug wholesalers drove fentanyl's deadly rise, report concludes

December 4, 2018
Fentanyl, a powerful synthetic opioid implicated in nearly 29,000 overdose deaths in the United States last year, most likely spread because of heroin and prescription pill shortages, and also because it was cheaper for drug ...

Global review reports on administration of children's antibiotics

December 4, 2018
Researchers analyzing the sales of oral antibiotics for children in 70 high- and middle-income countries found that consumption varies widely from country to country with little correlation between countries' wealth and the ...

Opioid prescriptions from dentists linked to youth addiction risk

December 3, 2018
Teens and young adults who receive their initial opioid prescriptions from their dentists or oral surgeons are at increased risk for opioid addiction in the following year, a study from the Stanford University School of Medicine ...

Rise in meth and opioid use during pregnancy

November 29, 2018
Amphetamine and opioid use in pregnancy increased substantially over the last decade in the United States, a new Michigan Medicine-led study finds. And a disproportionate rise occurred in rural counties.

Mouse model aids study of immunomodulation

November 19, 2018
Because mice do not respond to immunomodulatory drugs (IMiDs), preclinical therapeutic and safety studies of the effects of IMiDs have not been possible in existing types of mice. This has led to an inability to accurately ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.